HCW Biologics
HCWB
12 hedge funds and large institutions have $1.25M invested in HCW Biologics in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 0 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
0% more funds holding
Funds holding: 12 → 12 (0)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
15% less capital invested
Capital invested by funds: $1.48M → $1.25M (-$226K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$37.6K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$23.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.1K |
| 4 |
BlackRock
New York
|
+$7.86K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
HighTower Advisors
Chicago,
Illinois
| $495K | +$23.6K | +42 | +5% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $191K | +$10.1K | +18 | +5% |
|
|
BCM
3
Bridgeway Capital Management
Houston,
Texas
| $160K | +$37.6K | +67 | +28% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $121K | +$5.05K | +9 | +4% |
|
|
5
BlackRock
New York
| $94K | +$7.86K | +14 | +8% |
|
|
6
Two Sigma Investments
New York
| $87K | -$27K | -48 | -23% |
|
7
State Street
Boston,
Massachusetts
| $47K | +$1.69K | +3 | +3% |
|
|
CAM
8
Cresset Asset Management
Chicago,
Illinois
| $39K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $8K | +$6.74K | +12 | +400% |
|
10
UBS Group
Zurich,
Switzerland
| $5K | +$1.12K | +2 | +29% |
|
|
FWM
11
Focused Wealth Management
Newburgh,
New York
| $2K | – | – | – |
|
12
Morgan Stanley
New York
| $1K | – | – | – |
|
HCWB Hedge Fund Activity: Q2 2022 in Review
12 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in HCW Biologics (HCWB) for Q2 2022, worth a combined $1.25M — down 15% from $1.48M a quarter earlier.
Fund positioning in HCWB was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 8 added to existing stakes and 1 trimmed.
The largest buyer was Bridgeway Capital Management, adding an estimated $37.6K. The largest seller was Two Sigma Investments, cutting an estimated $27K.
- 12 institutional investors held HCW Biologics (HCWB) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $1.25M of HCW Biologics stock for Q2 2022, down 15% quarter-over-quarter.
- 0 funds opened new HCW Biologics positions in Q2 2022 and 0 closed out.
- The largest HCW Biologics buyer in Q2 2022 was Bridgeway Capital Management, an estimated $37.6K added.
- The largest HCW Biologics seller in Q2 2022 was Two Sigma Investments, an estimated $27K sold.
Based on aggregated 13F filings for Q2 2022.